Highlife Medical

VI Partners invests in Highlife Medical

Posted Posted in Fund news

VI Partners proudly announces its investment into Highlife Medical. Highlife Medical develops a new 2-component (“valve in ring”) transcatheter mitral valve replacement systems offering unique features for the treatment of mitral valve insufficiency. The transcatheter mitral valve implantation market is regarded as one of the most attractive markets in medical devices and is expected to Read the full article…

Medlumics Logo

VI Partners co-leads investment in Medlumics’ €14M Series E round

Posted Posted in Fund news, News

Madrid, Spain, October 6th 2020:
Medlumics, which develops Ablaview®, a unique RF irrigated ablation catheter system that merges photonics and miniaturized optics to guide device placement and directly assess the ablation lesions in real time, announces today the closing of a €14 million Series E financing, co-led by Asabys Partners (through the fund Sabadell Asabys Health Innovation Investments), VI Partners and CDTI Innvierte, with the participation from historical investors Andera Partners, Caixa Capital Risc and Innogest Capital. Several of the investors joining this round were investors in Endosense, a company in the same space acquired by Abbott (St. Jude Medical) in 2013 for more than USD 300 million.

VI Partners

A new fund advised by VI Partners made its first closing, a major achievement in the current environment

Posted Posted in Firm news, Fund news

A new fund advised by VI Partners made a first closing in April 2020 with CHF 75m (EUR 71m). It has been supported by its anchor investors Venture Incubator, an evergreen investment structure with corporate investors (ABB, Bühler, Crédit Suisse, ETH, Hilti, McKinsey, Nestlé, Schindler, Sulzer, Suva, ZKB), the European Investment Fund (EIF) – under Read the full article…

iOnctura Logo

iOnctura raises EUR 15m in Series A financing

Posted Posted in Fund news, News, Portfolio News

Amsterdam, The Netherlands – January 23, 2020: iOnctura B.V., a clinical stage biopharmaceutical company, developing a pipeline of next generation molecules targeting cancer and fibrosis, announces today the closing of a EUR 15 million Series A financing. The financing was led by INKEF Capital and co-led by VI Partners with participation by new investors Schroder Read the full article…

Araris Logo

Araris Biotech AG closes seed financing round of CHF 2.5m

Posted Posted in Fund news, News, Portfolio News

Zurich, Switzerland – August 20, 2019: Araris Biotech AG announced today the closing of an oversubscribed seed financing round of CHF 2.5 million with participation of Swiss investors Redalpine, Schroder Adveq and VI Partners. The proceeds will be used to develop a pipeline of proprietary antibody-drug conjugates (ADCs). Araris’ co-founder and Chief Executive Officer, Dr. Read the full article…

Amal Therapeutics Logo

Boehringer Ingelheim acquires AMAL Therapeutics

Posted Posted in Fund news, Portfolio News

Boehringer Ingelheim today announced its acquisition of all shares of AMAL Therapeutics SA, a private Swiss biotechnology company focused on cancer immunotherapy and advancing first-in-class therapeutic cancer vaccines derived from its technology platform KISIMA. AMAL’s lead vaccine ATP128 is currently developed for stage IV colorectal cancer and is slated to begin first-in-human trials later this Read the full article…

L.E.S.S. Logo

L.E.S.S. SA raises CHF 14m to accelerate the industrialization of their products in the automotive market.

Posted Posted in Fund news, News, Portfolio News

L.E.S.S. SA, a high tech company manufacturing a new generation of ultra-bright and ultra-thin lighting systems, announced today the closing of a CHF 14 million Series B financing round to accelerate the industrialization of their products in the automotive market. The round was led by new private and existing investors. L.E.S.S. SA was founded in Read the full article…

Altoida Logo

Altoida Raises $6.3m Series A to predict Alzheimer’s disease risk using AI, machine learning and augmented reality

Posted Posted in Fund news, News, Portfolio News

Altoida Inc. today announced a $6.3 million round of venture capital financing to bring its FDA-cleared and CE Mark-approved medical device and brain health data platform to patients, physicians and researchers around the globe. Led by a team of esteemed neuroscientists, physicians and computer scientists, Altoida uses digital biomarkers to drive better clinical outcomes for Read the full article…

Sequana Logo

Sequana Medical raises €27.5 million in IPO

Posted Posted in Fund news, News, Portfolio News

Sequana Medical NV – (“Sequana Medical”, the “Company”), a commercial stage medical device company focused on the development of innovative treatment solutions for the management of liver disease, heart failure, malignant ascites and other fluid imbalance disorders, today announces the results of its initial public offering of new shares, with the admission of all of Read the full article…

Kuros Biosciences Logo

Kuros announces final result of capital increase – total gross proceeds of CHF 16.1m raised

Posted Posted in Fund news, News, Portfolio News

Kuros Biosciences (SIX: KURN) (the Company or Kuros) announces the final number of offered shares and gross proceeds from the rights offering and share placement, first announced on November 29, 2018, in which a total of 8,013,306 new registered shares of Kuros sourced from the ordinary and authorized share capital with a nominal value of CHF 1.00 Read the full article…

Nexthink Logo

Nexthink raises $85m to help companies improve the digital employee experience

Posted Posted in Fund news, News, Portfolio News

Nexthink®, the leader in digital employee experience management software for enterprises, today announced it has secured an $85 million funding round. The financing was led by Index Ventures and includes participation from returning investors Highland Europe, Forestay Capital, VI Partners, Auriga Partners and Galéo Capital and new investors TOP Funds and Olivier Pomel, Co-founder and CEO of Datadog. Over the past few years, Nexthink has Read the full article…

Ledgy Logo

Equity management platform Ledgy secures €1m for expansion in Europe

Posted Posted in Fund news, News, Portfolio News

Ledgy AG, Zurich (Switzerland), provider of equity software for private companies, has collected 1 million euros in a successful seed round. The company secured funding from a strong alliance of European investors: In addition to btov Partners (St. Gallen, Switzerland), Creathor Ventures (Bad Homburg, Germany) and VI Partners (Zug, Switzerland) are involved. Daniel Gutenberg and Read the full article…

Amal Therapeutics Logo

AMAL Therapeutics finalises €29m (CHF 33.2m) Series B round

Posted Posted in Fund news, News, Portfolio News

AMAL Therapeutics (AMAL), the Swiss biotech developing novel, peptide-based therapeutic cancer vaccines, today announces that it has completed the second closing of its Series B financing round. The second and final tranche of €21.2 million (CHF 24.2 million) brings the total round to just over €29 million (CHF 33.2 million). The Company will use the Read the full article…

Euippo Logo

Equippo closes financing round and expands to Belgium

Posted Posted in Fund news, News, Portfolio News

Equippo, an online marketplace for construction equipment, has acquired a Berlin-based startup and simultaneously expanded its services with a permanent auction yard in Belgium. These strategic moves come after Equippo closed a new financing round from existing investors. Equippo’s online platform, allows customers to purchase used heavy equipment from the US and Europe selling as high as 500,000 US dollars. Read the full article…

Sequana Logo

Sequana Medical establishes new corporate headquarters in Ghent, Belgium and raises €8.5m from Newton Biocapital, PMV and SFPI-FPIM and others

Posted Posted in Fund news, News, Portfolio News

Sequana Medical NV (“Sequana Medical” , the “Company” ), a commercial stage medical device company focused on the development of innovative treatment solutions for the management of liver disease, heart failure, malignant ascites and other fluid imbalance disorders, announces today the opening of its new corporate headquarters in Ghent, Belgium, at the epicentre of the Flanders healthcare hub, and Read the full article…

CeQur Logo

Analysis demonstrates CeQur PAQ insulin delivery device is highly cost effective for people with Type 2 Diabetes not in glycemic control

Posted Posted in Fund news, News, Portfolio News

CeQur® today announced that the Journal of Health Economics and Outcomes Research (JHEOR) published online an analysis evaluating the cost effectiveness of the company’s PAQ® Insulin Delivery Device. The analysis suggests that the simple three-day, wearable PAQ basal-bolus insulin delivery device is more cost-effective than multiple daily insulin injections (MDI) and results in a lifetime cost savings of more Read the full article…

Kuros Biosciences Logo

Kuros reports first patient treated in randomized controlled trial of MagnetOs in spinal fusion

Posted Posted in Fund news, News, Portfolio News

Kuros Biosciences (SIX: KURN) today announced that the first patient has been treated in an investigator-led multicenter randomized controlled study comparing MagnetOs with autologous bone in posterolateral spinal fusion. The University Medical Center Utrecht (UMCU) in the Netherlands is the principal investigating site for the study, which is entitled “A Randomized Controlled Trial of MagnetOs® Read the full article…

Sequana Logo

Sequana Medical reports positive data on use of the alfapump® in malignant ascites patients at the International Gynecologic Cancer Society

Posted Posted in Fund news, News, Portfolio News

Sequana Medical AG (“Sequana Medical”), a commercial stage medical device company focused on the development of innovative treatment solutions for the management of liver disease, heart failure, malignant ascites and other fluid imbalance disorders, announces today positive findings from its Retrospective Malignant Ascites Study. The study retrospectively evaluated 17 patients with malignant ascites that had been implanted with Read the full article…

Genkyotex Logo

Genkyotex announces positive outcome of the Phase 2 trial of GKT831 in primary biliary cholangitis from the second independent SMB review

Posted Posted in Fund news, News, Portfolio News

Genkyotex (Euronext Paris & Brussels: FR00011790542 – GKTX), a biopharmaceutical company and the leader in NOX therapies, announces today that the independent Safety Monitoring Board (SMB) for its Phase 2 trial of GKT831 for the treatment of Primary Biliary Cholangitis (PBC) held its second pre-planned data review meeting and recommended the continuation of the Company’s Read the full article…

Genkyotex Logo

Genkyotex announces complete enrollment in interim analysis cohort of phase 2 trial of GKT831 in primary biliary cholangitis

Posted Posted in Fund news, News, Portfolio News

Genkyotex (Euronext Paris & Brussels: FR00011790542 – GKTX), a biopharmaceutical company and the leader in NOX therapies, announces today that 90 patients have been randomized in its Phase 2 trial of GKT831 for the treatment of Primary Biliary Cholangitis (PBC). This represents the target number of patients required to conduct the pre-planned interim analysis. The Read the full article…

Jenavalve Logo

JenaValve Technology initiates U.S. Patient enrollment in early feasibility study of next-generation TAVR system for the treatment of severe aortic stenosis and severe aortic regurgitation

Posted Posted in Fund news, News, Portfolio News

JenaValve Technology, Inc., a developer and manufacturer of differentiated transcatheter aortic valve replacement (TAVR) systems, today announced initiation of patient enrollment in the Early Feasibility Study (EFS) of its next generation JenaValve Pericardial TAVR System using the Everdur™ transcatheter heart valve (THV) and CoronatixTM Transfemoral Delivery Catheter at NewYork-Presbyterian/ Columbia University Medical Center (CUMC), New York City, and MedStar Washington Hospital Center, Read the full article…

Sonic Emotion Logo

Sennheiser Invests in Dear Reality & Sonic Emotion to Enhance Its VR/AR Capabilities

Posted Posted in Fund news, News, Portfolio News

Sennheiser is aiming to strengthen its position as a leading provider of immersive audio solutions with an investment in Dear Reality, experts in spatial audio algorithms and audio VR/AR software, and the acquisition of technologies from Sonic Emotion, a developer of 3D audio software and processing solutions. Both companies have developed unique expertise and tools for Read the full article…

Myotest Logo

Suunto and Myotest announce technology collaboration

Posted Posted in Fund news, News, Portfolio News

Suunto, a global leader in sports precision instruments and Myotest, a global leader in advanced, accelerometer-based analysis and interpretation for digital sport, today announced technology collaboration for a new running solution. Suunto has a long heritage in building robust sports watches known for their precision and sports expertise targeted to performance oriented athletes, while Myotest’s personalized smart Read the full article…

Genkyotex Logo

Genticel and Genkyotex announce intention to enter into strategic combination

Posted Posted in Fund news, News, Portfolio News

Genticel (Euronext Paris & Brussels: FR00011790542 – GTCL), a biotechnology company developinginnovative immunotherapies, and Genkyotex, a Swiss privately-held biopharmaceutical company and the leader in NOX therapies, announced today that Genticel has signed a contribution agreement with the shareholders of Genkyotex pursuant to which, subject to the approval of Genticel’s shareholders at a meeting expected to be held in Read the full article…

inositec Logo

Inositec AG secures CHF1.4m in seed financing to advance new class of inositol hexaphosphate-based drug candidates

Posted Posted in Fund news, News, Portfolio News

Inositec, a pioneer in the development of life-saving small molecule drugs based on inositol hexaphosphate (IP6), announced today the closing of a CHF1.4 million (US$1.42 million) seed financing. Investors participating in the round included VI Partners via the Venture Incubator fund and Zürcher Kantonalbank. The proceeds will be used to progress a drug candidate from Read the full article…

Cell Medica Logo

Cell Medica Acquires Delenex Therapeutics

Posted Posted in Fund news, News, Portfolio News

Cell Medica, a leader in developing, marketing and manufacturing cellular therapeutics for cancer and viral infections, announced today the acquisition of Delenex Therapeutics AG, a privately held, clinical stage biopharmaceutical company focused on the development of locally and systemically applied antibody therapeutics. The acquisition will enable Cell Medica to accelerate the development of gene-modified immune Read the full article…

GAMAYA closes CHF 3.2 Million Series A to boost the deployment of their advanced crop analytics services

Posted Posted in Fund news, News, Portfolio News

Gamaya, provider of the world’s most advanced solution for large-scale diagnostics of farmland using hyperspectral imaging and artificial intelligence, announced it has raised 3.2 Million in a series A financing round. Investors include Sandoz Foundation, Peter Brabeck-Letmathe (Chairman of Nestle), Seed4Equity (social-impact investment fund), as well as well-established Swiss venture capital firm VI Partners. All Read the full article…

Amal Therapeutics Logo

Amal Therapeutics raises CHF 3 million

Posted Posted in Fund news, News, Portfolio News

Amal Therapeutics (Amal) completes CHF 3 million (EUR 2.75 million) Series A financing round with Boehringer Ingelheim Venture Fund (BIVF) as cornerstone investors. VI Partners and High-Tech Gründerfonds also participated in the round which will help progress Amal’s cancer vaccines. Amal Therapeutics is a Swiss biotech company developing and progressing therapeutic cancer vaccines. The company Read the full article…

Euippo Logo

Venture Incubator Invests in Equippo

Posted Posted in Fund news, News, Portfolio News

If you follow the Equippo blog, you’ll remember that Equippo announced its first financing round with b-to-v partners in June, 2015. Fast forward half a year, and we’re happy to announce the closing of our second major funding round with Swiss firm VI Partners. After celebrating Equippo’s first birthday on November 17th, this financing round comes at a Read the full article…

Kuros Biosciences Logo

Cytos Biotechnology and Kuros Biosurgery to combine to create Kuros Biosciences

Posted Posted in Fund news, News, Portfolio News

Cytos Biotechnology Ltd. (SIX:CYTN) (“Cytos”) and Kuros Biosurgery Holding AG (“Kuros”), today announced their intention to combine their businesses by way of an exchange of Kuros shares for new Cytos shares, subject to shareholder approval and other customary conditions. Cytos is listed on the main segment of the Swiss stock exchange (SIX Swiss Exchange) while Read the full article…

Mila Logo

Swisscom übernimmt Mehrheit an Startup Mila

Posted Posted in Fund news, News, Portfolio News

Mit Swisscom Friends bietet Swisscom ihren Kunden gemeinsam mit dem Startup Mila seit zwei Jahren einen zusätzlichen, flexiblen und raschen Vor-Ort-Kundensupport. Swisscom hat nun die Mehrheit am Startup Mila übernommen. Mit der Investition baut der Schweizer ICT-Anbieter seine Aktivitäten im Bereich Shared Economy weiter aus. Mit Swisscom Friends erhalten Kunden auf einfache Weise kompetente und Read the full article…

Acquisition of Activaero

Posted Posted in Fund news, News, Portfolio News

Vectura Group plc (LSE: VEC; “Vectura” or the “Company”) announces the acquisition of Activaero GmbH (“Activaero”) for a total consideration of €130 million (£108 million) to be funded through a combination of existing cash and equity. Activaero is a private German pharmaceutical company focused on the development of products for the treatment of respiratory diseases. Its proprietary smart Read the full article…

Endosense Logo

St. Jude Medical Acquires Endosense

Posted Posted in Fund news, News, Portfolio News

St. Jude Medical, Inc. (NYSE: STJ), a global medical device company, today announced the acquisition of Endosense SA, a Switzerland-based company that has pioneered contact-force measurement in catheter ablation. The acquisition adds to the company’s leading electrophysiology portfolio and provides a robust platform for future product development. St. Jude Medical has made an initial payment of approximately 159 Read the full article…

Neocutis Logo

Merz Pharma takes over Swiss dermatology specialist Neocutis

Posted Posted in Fund news, News, Portfolio News

Merz Pharma Group (Frankfurt am Main) today announced that it has acquired the Swiss pharmaceutical company Neocutis S.A. The acquisition of the company`s cosmeceutical skin care business strengthens Merz`s market position in the field of aesthetic dermatology. “Neocutis is an innovative company with an excellent presence on the U.S. market, and a promising potential for development,” said Philip Burchard, CEO of Read the full article…